Clinical Impact of Del Nido Cardioplegia in Adult Cardiac Surgery
- Conditions
- Heart; Surgery, Heart, Functional Disturbance as Result
- Interventions
- Drug: DEL NIDO CARDIOPLEGIADrug: COLD BLOOD BASED CARDIOPLEGIA
- Registration Number
- NCT04094168
- Lead Sponsor
- JESSICA GARCIA SUAREZ
- Brief Summary
Cardioplegia solutions have been used for myocardial protection in cardiac surgery for decades. Different cardioplegic strategies have been evaluated.
Del Nido cardioplegia was initially used in pediatric patients and has been expanding into adult cardiac centers over the last decade. It can be used as a single dose and it is a reasonable tool do decrease cardioplegic interventions. Recent meta-analysis based on 9 retrospective studies has shown that "clinical outcomes of Del Nido cardioplegia are noninferior to the outcomes of conventional cardioplegia in adult cardiac surgery".
To assess the potencial benefits of Del Nido cardioplegia we performed this clinical trial to evaluate superiority of Del Nido cardioplegia compared to cold blood cardioplegia in terms of myocardial protection and clinical-related outcomes. 474 participants will be randomized either into Del Nido cardioplegia protocol or into the cold blood cardioplegia protocol. Perioperative outcomes will be presented.
- Detailed Description
This clinical trial is performed at Puerta de Hierro Hospital in Spain. The protocol has been approved by institutional ethical committee and Spanish Agency of medicines and medical devices (AEMPS).
The aim of the study is to evaluate superiority of Del Nido cardioplegia solution compared to cold blood cardioplegia solution in terms of myocardial protection and clinical-related outcomes.
According to results in recent meta-analysis, the author estimated a total sample size of 474 participants to give 80 % of power at the 5% significant level.
Participants aged 18 years or older undergoing elective cardiac surgery are randomized 1:1 to receive Del Nido cardioplegia solution (study group) and cold blood cardioplegia solution (control group).
Primary outcome will be assessed by biochemical variables of myocardial injury (troponin T level at inmediate post-op, 3-12 hours, 12-24 hours, 24-48 hours post-op); and clinical variables: "Presence of acute myocardial infarction within 72 hours after surgery", "Prolonged low cardiac output", "Prolonged postoperative vasoplegia" within 48 hours after surgery and/or "Ventricular tachyarrythmias" within 24 hours after surgery.
Secondary outcomes include intraoperative variables of myocardial protection (incidence of ventricular fibrillation, inotropic and vasopressor support at the end of surgical intervention, cardiopulmonary bypass time, aortic cross-clamp time) and postoperative clinical outcomes variables (mechanical ventilation time, incidence of delirium, stroke, acute renal failure, atrial fibrillation, length of stay in intensive care unit, length of stay in hospital and In-hospital mortality).
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 474
- Patients age 18 years or older undergoing adult cardiac surgery.
- Elective surgical procedures requiring cardiopulmonary bypass and myocardial arrest.
- Emergency surgery.
- Patients on preoperative inotropic support and/or mechanical circulatory support.
- Patient who refuse to participate in the study.
- Lidocaine allergy.
- Port access mitral valve surgery.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Del Nido Cardioplegia solution DEL NIDO CARDIOPLEGIA 1 liter of Del Nido cardioplegia after aortic cross-clamp will be given. Additional dose will be applied if aortic cross-clamp exceeds 90 minutes or whenever cardiac activity is observed. Cold blood Cardioplegia solution COLD BLOOD BASED CARDIOPLEGIA Administering of cardioplegia using current standard of care blood-based cardioplegia protocol. An induction dose of whole blood cardioplegia will be given at a temperature of 4-8 degrees, with subsequent doses of cardioplegia every 20 minutes or whenever cardiac activity is observed.
- Primary Outcome Measures
Name Time Method Acute cardiovascular event. Up to 72 hours Composite outcome of clinical events "Prolonged low cardiac output", "Prolonged postoperative vasoplegia", "Ventricular tachyarrythmias" and/or "Acute myocardial infarction".
* Prolonged low cardiac output. Inotropic pharmacologic support more than 48 hours in intensive care unit and/or mechanical circulatory support.
* Prolonged postoperative vasoplegia. Vasopressor support more than 48 hours in intensive care unit.
* Ventricular tachyarrythmias. Ventricular fibrillation and hemodynamically unstable ventricular tachycardia within 24 hours after surgery.
* Acute myocardial infarction within 72 hours after surgery.Blood troponin levels. Up to 48 hours Biochemical variables of myocardial injury: Blood troponin levels measured at admission in intensive care unit, 12, 24, 48 hours post-op.
- Secondary Outcome Measures
Name Time Method Ventricular fibrillation after aortic cross-clamp removal. Intraoperative. Incidence of ventricular fibrillation after aortic cross-clamp removal (Y/N).
Defibrillation requirement. Intraoperative. Defibrillation requirement after aortic cross-clamp removal (Y/N).
Cardioplegia delivery. Intraoperative. Cardioplegia delivery (antegrade, retrograde, both).
Cardiopulmonary bypass time (CBP). Intraoperative. Duration of cardiopulmonary bypass (CBP) (min).
Length of stay in intensive care unit through study completion, an average 1 month. Length of stay in intensive care unit (days).
Length of stay in hospital through study completion, an average 6 months. Length of stay in hospital (days).
Postoperative ventricular ejection fraction change. through study completion, an average 6 months. Postoperative ventricular ejection fraction (LVEF) change (Y/N).
Mortality. through study completion, an average 6 months. Mortality (Y/N).
Aortic cross-clamp time Intraoperative. Duration of aortic cross-clamp time (min).
Return to cardiopulmonary bypass. Intraoperative Failure to separate from cardiopulmonary bypass (Y/N).
Intraoperative packed red blood cells transfusion. Intraoperative Intraoperative packed red blood cells transfusion (U).
Intraoperative maximal blood glucose concentration. Intraoperative Intraoperative maximal blood glucose concentration (mg/dl).
Postoperative atrial fibrillation. Up to 2 weeks. New-onset atrial fibrillation or hemodynamically unstable atrial fibrillation that requires treatment (Y/N).
Reoperation. Up to 24 hours. Reoperation within 24 hours after surgery (Y/N).
Inotropic or vasopressor support in intensive care unit. At admission in intensive care unit, 24, 48 hours. Inotropic or vasopressor support in intensive care unit (Y/N).
Duration of inotropic support after cardiopulmonary bypass. Up to 2 weeks. Duration of inotropic support after cardiopulmonary bypass (hours).
Time to extubation. Up to 2 weeks. Mechanical ventilation time (min).
Acute renal failure. Up to 2 weeks. Incidence of renal failure (Requirement for postoperative renal replacement therapy) (Y/N).
Ischemic stroke. Up to 2 weeks. Incidence of ischemic stroke (Y/N).
Delirium. Up to 2 weeks. Incidence of delirium (Y/N).
Postoperative packed red blood cells transfusion. Up to 1 week. Postoperative packed red blood cells transfusion (U)
Trial Locations
- Locations (1)
Puerta de Hierro Hospital
🇪🇸Majadahonda, Madrid, Spain